NECTIN4 and cancer: Nectin-4 is also broadly expressed in many normal epithelial tissues in low-to-moderate levels; however, its expression levels in cancers are much higher [93], resulting in an acceptable safety profile and therapeutic window for enfortumab vedotin [95].